Pharmaceutical Preparations
BioAge Labs, Inc. (BIOA) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 43/100 — a percentile rank of BioAge Labs, Inc.’s fundamentals against Manufacturing peers.
Consensus: Buy from 7 analysts (Buy 6 · Hold 1).
Average price target: $18.00 (+282.2% vs $4.71); range $8–$25.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 38 · Open-market sells: 0 · Net: +$72.6M
Coordinated block · likely financing, not open-market conviction.
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!